CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
James Park
Advertisement
James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.
Articles by James Park
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5